Chunbuk, Korea, Republic of
- Featured
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Phase
2Span
227 weeksSponsor
Mirati Therapeutics Inc.Incheon, Gwang'yeogsi
Recruiting
1-1 of 1